🚀 Medial Secures Investment on Shark Tank India - Fueling the Future of Professional Social Networking. 🔥
Login

News on Medial

Tata 1mg revenue nears Rs 2,400 Cr in FY25, trims losses

EntrackrEntrackr · 4m ago
Tata 1mg revenue nears Rs 2,400 Cr in FY25, trims losses
Medial

Tata 1mg, the digital healthcare platform backed by Tata Digital, continued its growth trajectory in the fiscal year ending March 2025 while straining its losses. Tata 1mg’s consolidated revenue rose 22% to Rs 2,392 crore in FY25 from Rs 1,968 crore in FY24, according to Tata Sons’ Annual Report for the fiscal year. Tata 1mg is a health tech startup for online orders of allopathic, ayurvedic, homeopathic medicines, vitamins, nutrition supplements, and other health products, delivered to the home. 1mg’s revenue was split across two entities: Tata 1mg Technologies, which clocked Rs 2,016.5 crore, and Tata 1mg Healthcare Solutions, which contributed Rs 375.5 crore in FY25. The company's total cost rose by 17% to Rs 2682 crore in FY25, up from Rs 2303 crore in FY24. The Gurugram-based company posted a consolidated loss of Rs 276 crore in FY25, 12% lower than the Rs 313 crore loss reported in FY24. On a unit basis, the company spent Rs 1.12 to earn a rupee of operating revenue in FY25. On the asset side, Tata 1mg reported total assets of Rs 2,025 crore at the end of FY25 while its total liabilities reached Rs 1,190 crore. In the e-health space, Tata 1mg competes with Reliance-backed Netmeds, PharmEasy, and Apollo 24/7. Tata Digital acquired a 55% stake in 1mg in June 2021 but has since gained around 8.5% additional stake in the e-medicine platform. According to TheKredible, Tata Digital currently holds a 63.5% stake in 1mg, which was last valued at 1.25 billion. Tata Digital reported a standalone revenue of Rs 546.9 crore and a loss of Rs 827.5 crore in FY25, indicating continued investment in its digital commerce bets including 1mg and other verticals such as BigBasket, Cult.fit, and the recently launched Tata Neu.

1

Related News

Tata 1mg’s revenue nears Rs 2,000 Cr in FY24; losses down by 75%

EntrackrEntrackr · 1y ago
Tata 1mg’s revenue nears Rs 2,000 Cr in FY24; losses down by 75%
Medial

Tata 1mg chased growth during FY22 and FY23 and its collection spiked over two-fold in both fiscal years. But the company appears to have prioritized the bottom line in the fiscal year ending March 2024. As a result, its revenue grew by only 21%, and at the same time it cut down losses by 75% in FY24. Tata 1mg’s revenue from operations increased to Rs 1,968 crore in FY24 from Rs 1,627 crore in FY23, its consolidated financial statements sourced from the Registrar of Companies (RoC) show. Income from the sale of medicines formed 81.3% of Tata 1mg’s total revenue which increased 24% to Rs 1,599 crore in FY24. Lab test fees, patient support programme, advertising, shipping, were other revenue drivers for the Gurugram-based firm. The Prashant Tandon-led company also earned Rs 23 crore from interest, gain of financial assets, and other miscellaneous avenues which pushed its total income to Rs 1,991 crore in FY24. See TheKredible for the detailed revenue breakup. Since 1mg operates with inventory, the cost of procurement of medicines accounted for 56% of the overall expenditure. This cost grew by just 8.5% to Rs 1,289 crore in FY24. Tata 1mg’s spends on employee benefits, information technology, legal, advertising, commissions, packaging, fulfillment, and other overheads took its total cost up by 20.4% to Rs 2303 crore in FY24. Head to TheKredible for the complete expense breakdown. The decent scale and controlled cost helped Tata 1mg to reduce losses by 75% to Rs 313 crore in FY24 from Rs 1,255 crore in FY23. Its EBITDA margin stood at -10.85% in FY24. On a unit level, Tata 1mg spent Rs 1.17 to earn a rupee in the previous fiscal year. Cevat: The primary reason for the substantial losses in FY23 was the FVTPL cost (non-cash in nature), which amounted to Rs 668 crore. Tata Digital acquired a 55% stake in 1mg in June 2021 but since then it gained around 8.5% additional stake in the e-medicine platform. According to TheKredible, Tata Digital currently holds a 63.5% stake in 1mg which was last valued at 1.25 billion. As per Fintrackr’s estimates, its enterprise value to revenue multiple stood at 4.87X. FY23-FY24 FY23 FY24 EBITDA Margin -71.66% -10.85% Expense/₹ of Op Revenue ₹1.78 ₹1.17 ROCE -341.99 NA While the focus on bottomline is understandable as part of a large umbrella like the Tata Group, where freedom is proportional to financial performance,Tata 1mg’s cost control measures have another reason. It is probably no longer worthwhile to acquire customers at a high cost where customers have basically flunked the loyalty test. That has made most e-commerce players a lot more reticent about indiscriminate discounting and the likes in favor of much more data led, targeted campaigns. Of course, with a turkey as large as Tata Neu around, one would expect Tata 1mg to get a lot more leeway however.

Walmart India trims losses to Rs 110 Cr in FY25 amid muted revenue growth

EntrackrEntrackr · 2m ago
Walmart India trims losses to Rs 110 Cr in FY25 amid muted revenue growth
Medial

Walmart India trims losses to Rs 110 Cr in FY25 amid muted revenue growth Walmart India, the wholesale and retail arm of the global retail giant, managed to reduce its losses in FY25 even as revenue growth remained subdued. Walmart India’s operating revenue grew by a modest 2.6% to Rs 5,331 crore in FY25, as compared to Rs 5,195 crore in FY24, as per its financial statement sourced from Tofler. Walmart makes money via wholesale trading, with significant contributions from both food and non-food products; sales of these products accounted for 99% of the total operating revenue. The company made Rs 43 crore from other income, comprising gains from financial instruments and interest on bank deposits, which pushed its total revenue to Rs 5,374 crore in FY25 from Rs 5,200 crore in FY24. On the expenditure front, the cost of materials, which formed nearly 90% of overall expenses, increased 3% to Rs 4,924 crore in FY25 from Rs 4,791 crore in FY24. Employee benefit expenses declined by 10% to Rs 139 crore, while finance costs fell 17% to Rs 57 crore. Transportation and collection charges saw a small increase to Rs 94 crore and Rs 44 crore, respectively. Overall, total expenses rose marginally by 2.4% to Rs 5,484 crore in FY25 from Rs 5,355 crore in FY24. Walmart India succeeded in narrowing its loss by 29% to Rs 110 crore in FY25 from Rs 154 crore in FY24. Its ROCE and EBITDA margin stood at -8.85% and -0.35% respectively. On a unit level, Walmart India spent Rs 1.03 to earn a rupee of revenue in FY25. The company had current assets worth Rs 765 crore, including Rs 59 crore in cash and bank balances during the same period. Flipkart Internet, the B2C arm of Flipkart, which is owned by Walmart, reported a 14% year-on-year increase in revenue for FY25, exceeding Rs 20,000 crore. During the same period, the company successfully reduced its losses by 37%, bringing them down to Rs 1,494 crore. Walmart India faces competition from organized retail and wholesale players, including Reliance Retail and Metro Cash & Carry.

Acko posts Rs 2,837 Cr revenue in FY25, trims losses by 37%

EntrackrEntrackr · 13d ago
Acko posts Rs 2,837 Cr revenue in FY25, trims losses by 37%
Medial

Acko posts Rs 2,837 Cr revenue in FY25, trims losses by 37% Following a 20% year-on-year rise in FY24, insurtech platform Acko sustained its momentum with 35% revenue growth in FY25. At the same time, the company also cut its losses by 37% during the same period. Acko’s revenue from operations surged to Rs 2,837 crore in FY25, compared to Rs 2,106 crore in FY24, according to its consolidated annual figures accessed from the Registrar of Companies (RoC). For the digital insurance provider, income from gross premium earned made up 73.5% of its total income, rising 31% to Rs 2,085 crore during the last fiscal year. Service contracts, recoveries from reinsurers, commissions, interest income from investments, and other miscellaneous income pushed total revenue to Rs 2,887 crore in FY25, up from Rs 2,160 crore in FY24. In terms of cost breakdown, employee benefit expenses declined slightly by 6% to Rs 334 crore in FY25 from Rs 355 crore in FY24, accounting for 10% of the company’s total costs. The firm also cut its advertising spend by 12% to Rs 497 crore, while commissions paid to sole selling agents rose 35% to Rs 283 crore during the previous fiscal. A large portion of the company’s expenses was grouped under miscellaneous costs, primarily comprising claims paid, premium on reinsurance ceded, and other office and administrative expenses. This category amounted to Rs 2,006 crore in FY25. Overall, the total expenses for the Accel-backed company rose 17% to Rs 3,312 crore in FY25, compared to Rs 2,830 crore in FY24. Stronger top-line and tighter cost control helped Acko to reduce its losses by 37% to Rs 424 crore in FY25. Its ROCE and EBITDA margin improved to -30.5% and -16%, respectively. On a unit basis, Acko spent Rs 1.17 to earn a rupee in FY25. The company’s current assets stood at Rs 1,798 crore, including Rs 28 crore in cash and bank balance at the end of FY25. According to TheKredible, Acko has raised over $458 million to date. General Atlantic is the largest external shareholder with a 10.7% stake, followed by Accel Partners and Elevation Capital. Acko’s competitor Digit Insurance reported Rs 2,088 crore operating revenue in Q2 FY26, while its profit after tax increased by 30% to Rs 116.5 crore during the same period.

Healthians posts Rs 263 Cr revenue in FY25; nears breakeven

EntrackrEntrackr · 6d ago
Healthians posts Rs 263 Cr revenue in FY25; nears breakeven
Medial

Healthians posts Rs 263 Cr revenue in FY25; nears breakeven Healthians didn't manage notable growth in the fiscal year ending March 2025. However, the WestBridge-backed company narrowed its losses by 89% year on year and neared break-even during the same period. The firm’s operating revenue increased 8% year-on-year to Rs 263 crore in FY25, up from Rs 243 crore in FY24, as per its consolidated financial statements filed with the Registrar of Companies (RoC). Including non-operating income of Rs 7 crore, the company’s total income grew 7% to Rs 270 crore during the year. Cost optimisation played a key role in supporting the company’s financial recovery. Total expenses declined 8% to Rs 275 crore in FY25, compared to Rs 298 crore last year. Among the major cost heads, employee benefits, the largest expense category, dropped 13% year-on-year to Rs 104 crore in FY25 from Rs 120 crore in FY24. Cost of materials contracted 7% to Rs 54 crore. Advertising costs rose 10% to Rs 43 crore. Meanwhile, depreciation and finance costs remained stable at Rs 29 crore and Rs 15 crore, respectively. The improvement in revenue and control of key expenses helped Healthians bring down its losses sharply by 89% to Rs 5 crore in FY25 from Rs 45 crore in FY24. The firm posted positive EBITDA of Rs 32 crore in FY25 with EBITDA margin of 12.17%. Its ROCE stood at 2.73% in the same period. On a unit basis, the company spent Rs 1.05 to earn a rupee of operating revenue in FY25. The firm’s current assets increased slightly to Rs 170 crore including cash and bank balances worth Rs 49 crore in the fiscal. According to startup data intelligence platform TheKredible, Healthians has raised a total of $75 million of funding till date, having WestBridge, BEENEXT, DG Ventures and Youwecan as its lead investors. The company’s founder and CEO, Deepak Sahni owns 6.5% of the company.

Cashify’s FY25 income nears Rs 1,100 Cr, losses shrink 80%

EntrackrEntrackr · 1m ago
Cashify’s FY25 income nears Rs 1,100 Cr, losses shrink 80%
Medial

Cashify’s FY25 income nears Rs 1,100 Cr, losses shrink 80% Cashify has demonstrated stellar financial performance in the fiscal year ending March 2025. While it reported a 17% rise in revenue, surpassing the Rs 1,000 crore threshold, the Gurugram-based firm also narrowed losses by 80% during FY25. Cashify’s operational revenue reached Rs 1,096 crore in FY25 from Rs 935.07 crore in FY24, the company’s consolidated annual financial statements sourced from the Registrar of Companies (RoC) show. Cashify allows users to buy and sell used electronics, focusing mainly on phones and laptops. The company partners with original equipment manufacturers such as Xiaomi, OnePlus, and Samsung to run exchange programs. The firm also works with e-commerce giants Amazon and Flipkart to streamline the trade of refurbished devices for customers. Sales of pre-owned devices contributed Rs 999 crore which grew 17% year-on-year during the last fiscal year. Revenue from services such as repairs and commissions grew 22% to Rs 97 crore. Other income, including interest on deposits, added Rs 26 crore to total income, which stood at Rs 1,12 crore for FY25. Cashify’s expenses increased by 12% to Rs 1,133 crore in FY25 against Rs 1,008 crore in FY24. The largest expense was the cost of material which accounted for 82% of the total cost, this expense rose by 15% to Rs 924 crore. Employee benefits cost remained almost unchanged at Rs 122 crore. Other overheads including selling, distribution, advertising, and miscellaneous expenses added another Rs 44 crore to the total expenditure. With revenue outpacing expenses, Cashify managed to narrow its losses by a whopping 80%, to Rs 10.5 crore in FY25 from Rs 53 crore in FY24. The company’s EBITDA margin was negative at -2.14%, and return on capital employed stood at -10.28% in the last fiscal year. As of March 2025, Cashify’s cash and cash equivalents stood at Rs 68 crore, which decreased by 25% from last year’s Rs 91 crore. Its current assets stood at Rs 424 crore in FY25, as compared to Rs 383 crore in FY24. While the firm ended the last fiscal year with a loss, co-founder Mandeep Manocha recently said that it expects to achieve full-year profitability by the end of the ongoing fiscal year (FY26). Cashify has raised $130 million across multiple funding rounds. According to TheKredible, NewQuest Capital is the largest external shareholder with a 19.5% stake, followed by Olympus and MIH Ecommerce Holdings. It competes with several players in the market including Greendust, InstaCash, and Yaantra.

Redcliffe Labs posts Rs 419 Cr revenue in FY25; narrows EBITDA losses

EntrackrEntrackr · 4m ago
Redcliffe Labs posts Rs 419 Cr revenue in FY25; narrows EBITDA losses
Medial

Redcliffe Labs posts Rs 419 Cr revenue in FY25; narrows EBITDA losses Diagnostics platform Redcliffe Labs has posted a 20% increase in its operating revenue to Rs 419 crore in FY25 from Rs 350 crore in FY24 and managed to narrow its EBITDA losses, as per the company’s press release. Diagnostics platform Redcliffe Labs has posted a 20% increase in its operating revenue to Rs 419 crore in FY25 from Rs 350 crore in FY24, as per the company’s press release. The Gurugram-based firm also managed to reduce its EBITDA losses from -38% to -21% during the same period. Founded by Aditya Kandoi, Redcliffe operates a nationwide network of over 80 labs and claims to have the widest home sample collection footprint in the country. Diagnostic services contributed over 95% of the company’s revenue in FY25, with the rest coming from product sales and other operating income. The company said it diagnosed over 2.5 million cases last fiscal and continues to focus on expanding in underserved regions, with more than 70% of its testing volumes now coming from Tier II cities and beyond. On the profitability front, Redcliffe reported a gross margin of 70% in FY25 and is aiming to expand it to 74% in FY26. It has also set a revenue target of Rs 560 crore for the ongoing fiscal through organic growth and strategic acquisitions. “We are transforming lives and making diagnostics a first-line solution for millions who were previously underserved,” said Kandoi. The company plans to expand its presence to over 300 cities with 150 labs by FY28. According to startup data platform TheKredible, Redcliffe has raised $113 million to date, including a $42 million Series C round led by LeapFrog. It also acquired Bengaluru-based Celara Diagnostics in a $7 million deal. Redcliffe competes with players like PharmEasy-owned Thyrocare, Tata 1mg, and Healthians.

Download the medial app to read full posts, comements and news.